Frontlight ResearchEarly access
Taking peoplePhase 4
Semaglutide and wound closure time in people with diabetic foot ulcers
Tests whether semaglutide changes how fast diabetic foot wounds close in adults.
Key facts
- Who runs it
- Radboud universitair medisch centrum Stichting
- Where
- Netherlands1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Healing Diabetic Foot Ulcers with Semaglutide
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 70 people, planned
- Started
- 29 Jul 2026
- Expected to end
- 1 Jan 2028
- Type of study
- Interventional
- Record updated
- 19 May 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with type 2 diabetes who have an open foot wound (diabetic foot ulcer). It tests whether semaglutide helps the wound close faster.
- Age
- Over 18 years
- Sex
- All sexes
- Disease stage
- Type 2 diabetes with an active diabetic foot ulcer.
- Earlier treatment
- People cannot join if they now use, or used in the previous 6 months, a GLP-1RA or GLP-1/GIP co-agonist medicine.
Main reasons for not taking part
- Allergy to the contents of semaglutide injections
- Current pregnancy
- Past pancreatitis (inflamed pancreas) caused by a GLP-1RA medicine
- End-stage kidney disease (estimated-GFR <15 mL/min/m2) or on kidney replacement treatment such as dialysis
- Current anti-inflammatory treatment such as prednisolone, or life expectancy <3 months
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Have type 2 diabetes mellitus (T2DM)
- Presence of an active diabetic foot ulcer
- Age >18 years
- Be proficient in either Dutch or English
Who cannot take part
- Those with current use or who used a GLP-1RA or GLP-1/GIP co-agonist in the previous 6 months
- Previous pancreatitis attributed to use of GLP-1RA
- Current use of anti-inflammatory therapy, e.g. prednisolone
- Any contra-indication for semaglutide as outlined in the EPAR (which only consists of allergy to the contents of semaglutide injections)
- End-stage renal disease (defined as estimated-GFR <15 mL/min/m2 or the use of renal replacement therapy)
- Current pregnancy
- Life expectancy <3 months
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To demonstrate the effect of semaglutide on the time to wound closure in patients with a diabetic foot wound.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Healing Diabetic Foot Ulcers with Semaglutide
- Plain-language title
- Semaglutide and wound closure time in people with diabetic foot ulcersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 19 May 2026